



**Uscom**

ASX Media Release

---

## Uscom BP+ Contracted Into UK NHS Supply Chain

**Sydney, Australia: 14th March 2016:** Uscom (ASX code: UCM) (the **Company** or **Uscom**), a revenue stage, cardiovascular medical technology company, today notified the market of the awarding of a two year contract with a further two year option to the Uscom BP+ UK distributor, MediMax Global UK Ltd, for supply of Uscom BP+ central blood pressure devices into the UK NHS Supply Chain. The NHS Supply Chain provides cost-effective products into the UK NHS market including more than 1000 NHS trusts and Healthcare organization.

Following a review of central BP devices, contracts were awarded for two devices, the Uscom BP+ and the Welch Allyn 7100BP.

Central BP and pulse wave analysis is the new frontier in BP monitoring. Following invasive validation in adults, the Uscom BP+ was recently validated in children from 1 to 18 years old at The Great Ormond Street Hospital for Children, with results presented last month at the US Society for Critical Care Medicine in Orlando. The study demonstrated BP+ noninvasively provided equivalent results to cardiac catheters in children as young as 1 year old. This proof of effectiveness sets the BP+ device apart from its competitors and confirms the integrity of the science underlying the device and confirms its application in critical care and as a guide for advanced treatment of hypertension. This has led to the BP+ being used as a physiologic monitor on the International Space Station, and its inclusion as the preferred technology in an international hypertension drug trial currently being run by a European pharmaceutical leader.

The principle of MediMax, Mr Andrew Larwood, said *"this provides us with direct access through the NHS to the UK market for the next 4 years, starting 1<sup>st</sup> June 2016. The NHS is very progressive and technologically aware, and this contract is the outcome of their investigation of a number of devices in the market proposing to measure central BP and to offer cost effective solutions to the NHS for the improved management of hypertension and vascular care."*

Executive Chairman of Uscom, Associate Professor Rob Phillips said, *"This contract facilitates sales into over 1000 UK Hospital trusts and into GP practices, and is the foundation for the European marketing of the BP+. The BP+ has TGA (Australian), CE (European) and FDA (USA) approval, and we are mid CFDA (China) application now. BP+ is currently being prepared for global release to market, and we are negotiating world wide with partners in Pharma and clinical markets to deliver this sector leading technology rapidly and profitably, particularly in the USA, where we have both technology and price advantages over our competitors."*

Uscom manufactures and markets the USCOM 1A, the Uscom BP+, and Uscom SpiroSonic digital ultrasonic spirometry technologies. These premium digital devices are changing the way we diagnose and treat cardiovascular and pulmonary diseases, including hypertension, heart failure, asthma, COPD, occupational lung disease and sleep disorders. The products are integral for optimising management of sepsis and guidance of fluid, inotropes and vasoactive therapies in critical care monitoring, and in clinical and home care delivered asthma and COPD medications.



**Uscom**

## ASX Media Release

---

### About Uscom

Uscom Limited (UCM) is an ASX listed innovative medical technology company specialising in development and marketing of premium cardiovascular and pulmonary medical devices. Uscom has three practice leading suites of devices in the field of cardiac, vascular and pulmonary monitoring; the USCOM 1A, Uscom BP+ and the Uscom SpiroSonic spirometers. All Uscom devices are premium resolution, and deploy innovative and practice leading technologies with FDA, CE, CFDA and TGA regulatory approval, and which are currently being marketed into global distribution networks.

The USCOM 1A is a simple to use, cost-effective and non-invasive advanced haemodynamic monitor that measures cardiovascular function, detects irregularities and is used to guide treatment. The USCOM 1A device has major applications in Paediatrics, Emergency, Intensive Care Medicine and Anaesthesia, and is the device of choice for management of adult and paediatric sepsis, hypertension, heart failure and for the guidance of fluid, inotrope and vasoactive cardiovascular therapy.

The Uscom BP+ is a supra systolic oscillometric Central Blood Pressure monitor which measures blood pressure and blood pressure waveforms only previously available using cardiac catheterisation. The Uscom BP+ replaces conventional and more widespread sub systolic blood pressure monitors, and is the emerging standard of care measurement in hypertension, heart failure and vascular health. The Uscom BP+ provides a highly accurate and repeatable measurement of central and brachial blood pressure and pulse pressure waveforms using a familiar upper arm cuff. The BP+ is simple to use and requires no complex training with applications in hypertension, heart failure, intensive care, general practice and home care.

Uscom SpiroSonic digital ultrasonic spirometers are high fidelity, digital, pulmonary function testing devices based on multi path ultrasound technology. They are simple and accurate to use and provide research quality pulmonary function testing in small hand held devices that can be used in research, clinical and home care environments. The devices are specialised for assessment of COPD, sleep disordered breathing, asthma, industrial diseases and monitoring of pulmonary therapeutic compliance.

For more information, please visit: [www.uscom.com.au](http://www.uscom.com.au)

### Uscom Contacts

Associate Professor Rob Phillips  
Executive Chairman  
[rob@uscom.com.au](mailto:rob@uscom.com.au)

Catherine Officer  
Company Secretary  
[secretary@uscom.com.au](mailto:secretary@uscom.com.au)